Last reviewed · How we verify
Lymphazurin (ISOSULFAN BLUE)
At a glance
| Generic name | ISOSULFAN BLUE |
|---|---|
| Sponsor | Covidien |
| Drug class | isosulfan blue |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
- Localized swelling
- Mild pruritis
Key clinical trials
- Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer (NA)
- Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection (PHASE3)
- Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation
- Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake (NA)
- ICG and SLN Mapping (EARLY_PHASE1)
- Intraoperative Evaluation of Axillary Lymphatics (NA)
- A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping (PHASE2)
- Axillary Management After Neoadjuvant Chemotherapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lymphazurin CI brief — competitive landscape report
- Lymphazurin updates RSS · CI watch RSS